Osimertinib improves PFS in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC)...

The antibody-drug conjugate trastuzumab deruxtecan delays cancer growth for women with hormone receptor-positive (HR+)...

According to a new study presented at the 2024 ASCO Annual Meeting, adding the antibody-drug conjugate...

For patients with locally advanced oesophageal adenocarcinoma that can be treated with surgery, chemotherapy treatment...

The management of bladder cancer is evolving rapidly, with a new regimen recently approved for patients...

Review aims to implement a more personalised and multidisciplinary approach in treatment of menopause...

The Congressional Caucus heard how a unique partnership has significantly increased both the quality and...

Michelle, a 46-year-old female, underwent biopsy of a lesion in her left sided chest musculature in...

In this issue, highlights from the 2023 Gathering Around Cancer as well as national and international...

More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that...

The European Society for Medical Oncology and the American Society of Clinical Oncology (ESMO and ASCO)...

Results from a number of highly anticipated phase 3 clinical trials across the range of gynaecological...